ライフサイエンスコーパス: budesonide

1 xacerbation rate was reduced by 38.5% versus budesonide.

2 (P= .018) with budesonide/formoterol versus budesonide.

3 success with rifaximin, tinidazole, and oral budesonide.

4 sed release of IL-8, even in the presence of budesonide.

5 eceive placebo or the inhaled corticosteroid budesonide.

6 magnitude as that achieved by treatment with budesonide.

7 , similar in magnitude to that obtained with budesonide.

8 t with B[a]P and similar tumors treated with budesonide.

9 hway and MAPK cascade were also regulated by budesonide.

10 antagonize the effects of dexamethasone and budesonide.

11 significant resistance to chemoprevention by budesonide.

12 flammatory activity to the standard steroid, budesonide.

13 itial study was the synthetic glucocorticoid budesonide.

14 a systemic effect) occurred at all doses of budesonide.

15 were enrolled in a 12-week trial of inhaled budesonide.

16 he suppressive effects of the corticosteroid budesonide.

17 d with IL-17A and/or IL-22, with and without budesonide.

18 a underwent an 8-week treatment with inhaled budesonide.

19 Subjects with incident EoE (n = 25) received budesonide 1 mg twice daily, either nebulized and then s

20 They received 7 days of DOICS (budesonide 1,600 mug) and a test for nonadherence based

21 Neither the potent glucocorticoid, budesonide (10-7 M), nor a NO donor inhibited NF-kappaB

22 asone (100 nM), dexamethasone (1 microM), or budesonide (100 nM).

23 The effect of budesonide (100 pM to 10 microM) on VEGF secretion, expr

24 cebo (14% fall) (P < 0.05) with no effect of budesonide (12.5% fall) versus placebo (P > 0.05).

25 lar in all groups (43 [88%] of 49 in the TRF-budesonide 16 mg/day group, 48 [94%] of 51 in the TRF-bu

26 INTERPRETATION: TRF-budesonide 16 mg/day, added to optimised RAS blockade, r

27 Overall, at 9 months TRF-budesonide (16 mg/day plus 8 mg/day) was associated with

28 been randomly assigned to receive 400 mug of budesonide, 16 mg of nedocromil, or placebo daily for 4

29 treatment during pregnancy (n = 1231; 79.9% budesonide, 17.6% fluticasone, 5.4% beclomethasone, and

30 gmoidoscopy and histopathology scores in the budesonide 2.0-mg and 8.0-mg dose groups compared with p

31 50) and the cumulative incidence of relapse (budesonide 20.8% vs. placebo 16.3%, p = 0.547) and non-r

32 HD stage >2 with death as a competing event (budesonide 20.8% vs. placebo 32.6%, p = 0.250) and the c

33 ebulized AZD5423 (75 or 300 mug) once daily, budesonide 200 mug twice daily via Turbuhaler, or placeb

34 16.3%, p = 0.547) and non-relapse mortality (budesonide 28% (95% CI 15-41%) vs. placebo 30% (95% CI 1

35 zed double-blind placebo-controlled trial of budesonide (3 mg/day and 9 mg/day) and prednisolone (7.5

36 cerbation of their disease were treated with budesonide, 3 mg thrice daily.

37 re randomised to receive once daily, inhaled budesonide 400 mug (those aged <11 years 200 mug) or pla

38 mmunotherapy; group A (85 patients) received budesonide 400 mug twice daily and group B (40 patients)

39 ar lavage (BAL), subjects were randomized to budesonide (400 microgram, twice daily) or placebo treat

40 e 16 mg/day group, 48 [94%] of 51 in the TRF-budesonide 8 mg/day, and 42 [84%] of 50 controls).

41 of three, in a 1:1:1 ratio to 16 mg/day TRF-budesonide, 8 mg/day TRF-budesonide, or placebo, stratif

42 Following treatment, 34% of patients taking budesonide 9 mg and 46% of those taking prednisolone 7.5

43 Oral budesonide (9 mg once daily) is effective and safe for s

44 Oral budesonide, 9 mg daily was administered for 1 year and p

45 Budesonide, a corticosteroid with an extensive first-pas

46 Budesonide, a glucocorticoid, was proven to be a highly

47 For aerosol administration of budesonide, a nose-only technique has been developed tha

48 Cell treatment with the potent GC budesonide accelerated the decay of CCL2 mRNA (t(1/2) =

49 Hjortswang-Criteria, 80.0% of patients given budesonide achieved clinical remission compared with 37.

50 election was based on previous work in which budesonide added to the diet was found to inhibit pulmon

51 pical budesonide vs 33 of 105 (31.4%) for no budesonide (adjusted odds ratio, 0.93; 95% confidence in

52 However, the efficacy of budesonide against lung tumor progression decreased from

53 Budesonide also selectively accelerated the decay of eot

54 as 12.5% (95% CI 3-22%) under treatment with budesonide and 14% (95% CI 4-25%) under placebo (p = 0.8

55 ngs show that children with asthma receiving budesonide and beclometasone dipropionate have decreased

56 o permeability of two VEGF inhibitory drugs, budesonide and celecoxib, which are lipophilic and neutr

57 rategy has titrated combination therapy with budesonide and formoterol for both maintenance and relie

58 intenance and reliever (SMART) regimen (with budesonide and formoterol fumarate), and anti-IgE therap

59 bo-controlled, multicenter study to evaluate budesonide and mesalamine as short-term treatments for c

60 e long been needed, and recently two agents, budesonide and mycophenolate mofeteil, show promise in t

61 We further investigated whether budesonide and nedocromil modified pollution effects.

62 including dexamethasone, methylprednisolone, budesonide, and fluticasone, potentiated TGF-beta signal

63 In conclusion, oral budesonide appears to add minimal, if any, additional be

64 Infliximab or oral budesonide are helpful in patients with steroid-refracto

65 -controlled studies of IL-5 and oral viscous budesonide as well as new large studies examining the sa

66 symptoms were statistically significant with budesonide at 0.25 mg daily (p = 0.040), 0.25 mg twice d

67 Patients receiving budesonide at 0.5 mg twice daily via a face mask improve

68 thma (aged>/= 70, n=17) who had treated with budesonide (BUD) 400 mug/day plus Tulo 2 mg/day, were ra

69 ribe interactions between the glucocorticoid budesonide (Bud) and the Smo CRDs from both Drosophila a

70 ned to groups given pH-modified release oral budesonide capsules (9 mg budesonide once daily, Budenof

71 aluated the subgroup of nonsmoking subjects, budesonide caused a significant reduction in nasal condi

72 Treatment with budesonide caused no significant effect on nasal conditi

73 , and 4.02 for mannitol, sodium fluorescein, budesonide, celecoxib, and rhodamine 6G, respectively.

74 pectively, for mannitol, sodium fluorescein, budesonide, celecoxib, and rhodamine 6G.

75 om patients with COPD was less responsive to budesonide compared with those from nonsmokers and smoke

76 pression were sensitive to cyclosporin A and budesonide, compounds that inhibit T cell function, sugg

77 TRF-budesonide could become the first specific treatment for

78 Budesonide decreased circulating eosinophils and serum l

79 Budesonide decreased ex vivo generation of IL-5 and IFN-

80 ld recent-onset asthma, once daily, low-dose budesonide decreases SARE risk, reduces lung function de

81 ld recent-onset asthma, once daily, low-dose budesonide decreases SARE risk, reduces lung function de

82 rse events were possibly associated with TRF-budesonide-deep vein thrombosis (16 mg/day) and unexplai

83 A549 pulmonary cells, the dexamethasone- and budesonide-dependent repression of interleukin-1beta-ind

84 ne and budesonide, whilst dexamethasone- and budesonide-dependent repression of nuclear factor-kappaB

85 geted-release formulation of budesonide (TRF-budesonide), designed to deliver the drug to the distal

86 f four clinically important corticosteroids (budesonide, dexamethasone, triamcinolone acetonide, and

87 The potent glucocorticoid budesonide did not affect viral replication or cytokine

88 Budesonide did not decrease the occurrence of intestinal

89 The daily regimen of budesonide did not differ significantly from the intermi

90 Budesonide did not reduce allergen-induced sputum eosino

91 her cytokines and the topical glucocorticoid budesonide differentially regulate RANTES, monocyte chem

92 Mice treated with budesonide displayed an average of 90% inhibition of lun

93 omethasone-CFC - 548; fluticasone DPI - 445; budesonide DPI - 268; fluticasone-CFC MDI - 111.

94 os (beclomethasone-chlorofluorocarbon [CFC], budesonide dry powder inhaler [DPI], fluticasone DPI, fl

95 tients' ICS treatments to 180 mug or 200 mug budesonide dry powder inhaler twice daily for the entire

96 els, and AHR remained increased with inhaled budesonide during A alternata exposure, but all features

97 he expression profiles of genes modulated by budesonide during murine lung tumorigenesis.

98 domized to receive either a placebo enema or budesonide enema at a dose of 0.5 mg/100 mL, 2.0 mg/100

99 Budesonide enema is both effective and safe for the trea

100 The budesonide enemas were well tolerated.

101 Budesonide epimer R (BUDeR) and dexamethasone (DEX) were

102 the HEK growth medium as early as 1 h after budesonide epimer R treatment.

103 L-1R2, dexamethasone and, in particular, the budesonide epimer R were shown to effectively and rapidl

104 Our results suggest that budesonide exerts its effects of chemoprevention through

105 or ulcerative proctosigmoiditis who received budesonide foam 2 mg/25 mL twice daily for 2 weeks, then

106 -controlled trials evaluated the efficacy of budesonide foam for induction of remission in 546 patien

107 tly more frequently among patients receiving budesonide foam than placebo (Study 1: 38.3% vs 25.8%; P

108 tly greater percentage of patients receiving budesonide foam vs placebo achieved rectal bleeding reso

109 ol values were reported more frequently with budesonide foam.

110 ring the effect of treatment with intranasal budesonide for 2 weeks on nasal conditioning.

111 A total of 175 of 437 infants assigned to budesonide for whom adequate data were available (40.0%)

112 e SMART group consisted of two actuations of budesonide-formoterol (200 mug and 6 mug, respectively,

113 tandard group consisted of two actuations of budesonide-formoterol (200 mug and 6 mug, respectively,

114 onist (more than eight actuations per day of budesonide-formoterol in addition to the four maintenanc

115 The Single combination budesonide-formoterol inhaler Maintenance And Reliever T

116 manex), (3) montelukast (Singulair), and (4) budesonide/formoterol (Symbicort).

117 desonide/formoterol 400/12 mug twice daily + budesonide/formoterol 200/6 mug as needed for 12 weeks.

118 inhaler) with twice-daily ICS/LABA therapy (budesonide/formoterol 400 mug/12 mug; Turbuhaler).

119 g/d for 2 weeks and maintenance therapy with budesonide/formoterol 400/12 mug twice daily + budesonid

120 Budesonide/formoterol administration led to a significan

121 erbation occurred in 0 and 4 patients in the budesonide/formoterol and budesonide groups, respectivel

122 piratory tract infection (5.8% and 4.4%) for budesonide/formoterol and budesonide, respectively.

123 , the median FEV1 increased by 260 ml in the budesonide/formoterol arm compared with 5 ml in the plac

124 igned either to change control medication to budesonide/formoterol combination (BUD/FM) 320/9 mug/day

125 Twenty-five patients received budesonide/formoterol during the study.

126 Early treatment with inhaled budesonide/formoterol in patients at risk for acute resp

127 pared the efficacy and safety of combination budesonide/formoterol inhaler according to a single inha

128 A large data set from 3 studies comparing budesonide/formoterol maintenance and reliever therapy w

129 The effect of budesonide/formoterol on the FEV1 was maintained in the

130 T recipients with mild/severe BOS to receive budesonide/formoterol or placebo for 6 months.

131 were randomized 1:1 to 320/9 mug twice-daily budesonide/formoterol pMDI or 320 mug twice-daily budeso

132 In this population budesonide/formoterol pMDI was well tolerated over 12 mo

133 t to assess safety and asthma control with a budesonide/formoterol pressurized metered-dose inhaler (

134 (per patient-treatment year) were lower with budesonide/formoterol versus budesonide (incidence, 7.7%

135 sthma exacerbation was longer (P= .018) with budesonide/formoterol versus budesonide.

136 Aerosolized budesonide/formoterol versus placebo bid for up to 5 day

137 nd asthma control measures generally favored budesonide/formoterol.

138 initially received placebo were switched to budesonide/formoterol.

139 established lung adenomas were treated with budesonide, genotype-dependent differential effects of b

140 which the inhibitory effects of aerosolized budesonide, given for 1 min six times a week, were studi

141 </= 0.050) and 27% of patients in the 8.0-mg budesonide group (P </= 0.001) compared with 4% in the p

142 as achieved in 19% of patients in the 2.0-mg budesonide group (P </= 0.050) and 27% of patients in th

143 red in 17% (95% CI 6-28%) of patients in the budesonide group and 19% (CI 7-32%) in the placebo group

144 The reduction in adult height in the budesonide group as compared with the placebo group was

145 st 2 years, decreased growth velocity in the budesonide group occurred primarily in prepubertal parti

146 nfidence interval [CI], -1.9 to -0.5) in the budesonide group than in the placebo group (P=0.001) and

147 a patent ductus arteriosus was lower in the budesonide group than in the placebo group (relative ris

148 bronchopulmonary dysplasia was 27.8% in the budesonide group versus 38.0% in the placebo group (rela

149 A greater percentage of patients in the budesonide group were in clinical remission at week 8 th

150 4 patients in the budesonide/formoterol and budesonide groups, respectively.

151 rcine models was 3H-mannitol > fluorescein > budesonide > celecoxib > rhodamine 6G, with HPbetaCD, an

152 Budesonide has a high hepatic first-pass clearance and m

153 trials with cladibrine, pentoxifylline, and budesonide have failed to demonstrate benefits.

154 inue to demonstrate that steroids, including budesonide, have a greater acute benefit than aminosalic

155 ed the abilities of mesalamine, antibiotics, budesonide, immunomodulators, anti-tumor necrosis factor

156 the effectiveness of amoxicillin and topical budesonide in acute maxillary sinusitis.

157 Budesonide in combination with azathioprine is effective

158 Budesonide in combination with azathioprine is effective

159 in 3 times per day for 7 days and 200 mug of budesonide in each nostril once per day for 10 days.

160 ty of three doses of an enema preparation of budesonide in patients with active distal ulcerative col

161 uate the safety and estimate the efficacy of budesonide in patients with PBC, who have shown a subopt

162 Our goals were to assess budesonide in patients with treatment-dependent autoimmu

163 Four formulations of albuterol sulfate and budesonide in sieved and milled lactose, respectively, w

164 indicate that the chemopreventive effects of budesonide in the mouse lung tumorigenesis assay involve

165 hase III trial, we evaluated the efficacy of budesonide in the prophylaxis of acute intestinal GvHD a

166 ion, showed much lower systemic effects than budesonide in the thymus involution test, and possessed

167 , genotype-dependent differential effects of budesonide in wild-type and mutant mice were clearly rev

168 were lower with budesonide/formoterol versus budesonide (incidence, 7.7% vs 14.0% [P= .006]; rate rat

169 Budesonide-induced hyperglycemia and cosmetic adverse ef

170 trospective analysis suggests that nebulized budesonide inhalation suspension can be administered eff

171 Children were randomly assigned to receive a budesonide inhalation suspension for 1 year as either an

172 ates demonstrated the efficacy and safety of budesonide inhalation suspension in doses of 0.25 mg onc

173 All patients receiving budesonide inhalation suspension via face mask or mouthp

174 Budesonide inhibited both RANTES- and eotaxin promoter-d

175 -2B epithelial cells with the glucocorticoid budesonide inhibited MCP-4 mRNA expression.

176 Although budesonide inhibited the expression of chemokine mRNA to

177 At concentrations devoid of cytotoxicity, budesonide inhibited VEGF secretion as well as mRNA expr

178 ective for proinflammatory cytokines because budesonide inhibition of LPS-stimulated IL-10 release wa

179 rpose of this study was to determine whether budesonide inhibits expression of vascular endothelial g

180 BACKGROUND & AIMS: Budesonide is a corticosteroid with minimal systemic cor

181 Budesonide is a high-potency, second-generation corticos

182 Budesonide is a highly potent topical glucocorticosteroi

183 Budesonide is capable of inhibiting VEGF expression thro

184 Studies reporting that budesonide is effective for the treatment of collagenous

185 alicylates are therapeutic options; however, budesonide is more effective in achieving clinical and h

186 A dose of 2.0 mg/100 mL budesonide is the lowest effective dose.

187 nano- and microparticles produced sustained budesonide levels in the retina and other ocular tissues

188 xposed to budesonide, we engineered MSC with budesonide loaded PLGA microparticles.

189 RU486 treatment prevented budesonide-mediated inhibition of VEGF secretion and VEG

190 MSC efficiently internalized budesonide microparticles and exhibited 4-fold enhanced

191 randomly assigned to groups that were given budesonide MMX (9 mg or 6 mg), mesalamine (2.4 g, as ref

192 Budesonide MMX (9 mg) was safe and more effective than p

193 controlled trial to evaluate the efficacy of budesonide MMX for induction of remission in 509 patient

194 at week 8 among subjects given 9 mg or 6 mg budesonide MMX or mesalamine were 17.9%, 13.2%, and 12.1

195 at week 8 among subjects given 9 mg or 6 mg budesonide MMX or mesalamine were 28.5%, 28.9%, and 25.0

196 at week 8 among patients given 9 mg or 6 mg budesonide MMX or mesalamine were 33.3%, 30.6%, and 33.9

197 at week 8 among subjects given 9 mg or 6 mg budesonide MMX or mesalamine were 41.5%, 35.5%, and 33.1

198 Budesonide MMX(R) is a once-daily oral formulation of bu

199 in autoimmune hepatitis, and, in contrast to budesonide, mycophenolate mofetil has been effective in

200 ce therapy (n = 15); (2) currently receiving budesonide (n = 10); and (3) currently receiving oral pr

201 nal GvHD until day 100 observed in 91 (n =48 budesonide, n =43 placebo) evaluable patients was 12.5%

202 Of 7138 patients (n=3577 budesonide; n=3561 placebo), baseline symptom frequency

203 rmine whether subconjunctivally administered budesonide nano- and microparticles sustain retinal drug

204 hort, which was randomly assigned to receive budesonide, nedocromil, or placebo for 4-6 years, we det

205 Concentrations of budesonide of 26, 81, and 148 microg/liter of air (calcu

206 To determine the effects of budesonide on airway cell function, BAL cells were stimu

207 not negate the positive clinical benefits of budesonide on treating nasal inflammation.

208 though the intermittent-treatment group took budesonide, on average, for only 0.5 week of the year.

209 ified release oral budesonide capsules (9 mg budesonide once daily, Budenofalk, n = 30), mesalamine g

210 g analyses with the major subgroup that used budesonide only, association estimates were of similar m

211 Treatment of MSCs with glucocorticoids, budesonide or dexamethasone, enhanced IDO expression fol

212 odium-induced colitis, the platform carrying budesonide or mesalamine becomes more viscoelastic near

213 ition to daily treatment with either inhaled budesonide or oral zafirlukast over a one-year period.

214 early (within 24 hours after birth) inhaled budesonide or placebo until they no longer required oxyg

215 hs, the monkeys were treated daily with ICS (budesonide) or saline.

216 cal corticosteroids, such as fluticasone and budesonide, or dietary strategies, such as amino acid-ba

217 re and after 8 wk treatment with formoterol, budesonide, or placebo from atopic asthmatics.

218 io to 16 mg/day TRF-budesonide, 8 mg/day TRF-budesonide, or placebo, stratified by baseline urine pro

219 olled phase 2 trial to assess the ability of budesonide oral suspension (BOS), a novel muco-adherent

220 uate the safety and efficacy of oral viscous budesonide (OVB).

221 essurized metered-dose inhaler (pMDI) versus budesonide over 1 year in African American patients.

222 ter demonstrated a positive response to both budesonide (P = .02) and nedocromil (P = .01) compared w

223 uster demonstrated minimal responses to both budesonide (P = .12) and nedocromil (P = .56) compared w

224 The budesonide particles produced by the apparatus had a mas

225 More than 90% of all budesonide patients had a normal adrenocorticotropin (AC

226 r inhaled corticosteroid exposure (943.5 mug budesonide per day [1502.5] vs 684.3 mug budesonide per

227 mug budesonide per day [1502.5] vs 684.3 mug budesonide per day [390.5], respectively; ratio of means

228 ause of the poor solubility of celecoxib and budesonide, permeability studies were conducted with 5%

229 Budesonide-PLA nano- (345 nm) and microparticles (3.6 mi

230 After subconjunctival administration, both budesonide-PLA nano- and microparticles produced sustain

231 Subconjunctivally administered budesonide-PLA nano- and microparticles sustain retinal

232 Budesonide-PLA nano- and microparticles were administere

233 f budesonide plus formoterol with fixed-dose budesonide plus formoterol and fixed-dose fluticasone pl

234 ), 2250 asthmatics were randomly assigned to budesonide plus formoterol maintenance and reliever ther

235 matics and compared an adjustable regimen of budesonide plus formoterol with fixed-dose budesonide pl

236 maintenance and reliever therapy, fixed-dose budesonide plus formoterol, or fixed-dose fluticasone pl

237 After 2 weeks using a 320 mug twice-daily budesonide pMDI, patients were randomized 1:1 to 320/9 m

238 onide/formoterol pMDI or 320 mug twice-daily budesonide pMDI.

239 ted 4-fold enhanced IDO activity compared to budesonide preconditioned and naive MSC, resulting in a

240 In a lung tumor bioassay, budesonide produced 70% inhibition of tumor multiplicity

241 Mycophenolate mofetil, budesonide, rapamycin, and 6-thioguanine are promising t

242 Mycophenolate mofetil, budesonide, rapamycin, and 6-thioguanine have been effec

243 Budesonide rectal foam was well tolerated and more effic

244 d, phase 3 trials to evaluate the ability of budesonide rectal foam, formulated to optimize retention

245 In vitro fluticasone and budesonide reduced MR1 surface expression twofold and de

246 uggest that long-term treatment with inhaled budesonide reduces airway cell generation of cytokines,

247 ency of 65% and 99%, respectively, sustained budesonide release in vitro.

248 oral formulation of budesonide that extends budesonide release throughout the colon using multi-matr

249 5.8% and 4.4%) for budesonide/formoterol and budesonide, respectively.

250 All three doses of budesonide resulted in more than 80% inhibition of pulmo

251 esalamine (RR, 0.67; 95% CrI, 0.39-1.08) nor budesonide (RR, 0.86; 95% CrI, 0.61-1.22), reduced the r

252 rapy (RR, 0.04; 95% CrI, 0.00-0.14), but not budesonide (RR, 0.93; 95% CrI, 0.40-1.84), reduced the r

253 orticoid receptor in the observed effects of budesonide, secretion and mRNA expression studies were a

254 Met772 carriers on budesonide showed a significant improvement in forced ex

255 Budesonide significantly improved stool consistency and

256 lower among those who received early inhaled budesonide than among those who received placebo, but th

257 e MMX(R) is a once-daily oral formulation of budesonide that extends budesonide release throughout th

258 s successfully treated with prednisolone and budesonide, the model will be helpful to develop and tes

259 hs, with a safety profile similar to that of budesonide; the asthma exacerbation rate was reduced by

260 therapy or daily zafirlukast therapy, daily budesonide therapy produced greater improvements in pre-

261 Budesonide therapy was associated with a low frequency o

262 ed trial of AIH treatment to date, comparing budesonide to prednisone.

263 able to show any benefit for the addition of budesonide to standard GvHD prophylaxis.

264 ze retention and provide uniform delivery of budesonide to the rectum and distal colon, to induce rem

265 Budesonide-treated children with asthma had a slight but

266 Budesonide treatment also decreased allergen-induced air

267 nificant interaction (P=0.002) was found for budesonide treatment and the AC9 polymorphism.

268 Budesonide treatment improved the FEV(1), attenuated bot

269 After budesonide treatment there was a significant decrease in

270 ) were modulated back to normal levels after budesonide treatment when compared with the controls gro

271 ms complicated conversion from prednisone to budesonide treatment, and every patient developed at lea

272 mine gene expression changes associated with budesonide treatment.

273 ssed and 120 genes were underexpressed after budesonide treatment.

274 y of a novel targeted-release formulation of budesonide (TRF-budesonide), designed to deliver the dru

275 were randomly assigned to 200 mug of inhaled budesonide twice per day (n = 84) or placebo (n = 56) fo

276 whether there was a differential response to budesonide versus placebo for severe asthma exacerbation

277 For budesonide versus placebo, severe exacerbations requirin

278 For budesonide versus placebo, time to first SARE was longer

279 medication was reduced in patients receiving budesonide via face masks or mouthpieces relative to pla

280 more days were 32 of 102 (31.4%) for topical budesonide vs 33 of 105 (31.4%) for no budesonide (adjus

281 The mean exposure to budesonide was 104 mg less with the intermittent regimen

282 bo-controlled, cross-over study with inhaled budesonide was conducted in 14 subjects with allergic as

283 thy of rigorous study in severe disease, and budesonide was endorsed for study as front-line therapy

284 The chemopreventive efficacy of budesonide was examined in wild-type mice, mice with Ink

285 A daily low-dose regimen of budesonide was not superior to an intermittent high-dose

286 pediatric patients stimulated with IL-33 and budesonide was quantified.

287 mesalamine achieved clinical remission, but budesonide was superior to mesalamine (P = .0035).

288 Although budesonide was tolerated well, we observed a trend towar

289 able when cells were continuously exposed to budesonide, we engineered MSC with budesonide loaded PLG

290 Conversely, whereas dexamethasone and budesonide were highly effective inhibitors of interleuk

291 de (PLA) nano- and microparticles containing budesonide were prepared by a solvent evaporation techni

292 ed by RU486 but induced by dexamethasone and budesonide, whilst dexamethasone- and budesonide-depende

293 study (FACET) in which low and high doses of budesonide with and without formoterol were compared in

294 managed conservatively and treated with oral budesonide with resulting resolution of symptoms.